271 related articles for article (PubMed ID: 25991065)
1. Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability.
Fadke J; Desai J; Thakkar H
AAPS PharmSciTech; 2015 Dec; 16(6):1434-44. PubMed ID: 25991065
[TBL] [Abstract][Full Text] [Related]
2. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
3. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
Sun W; Ni R; Zhang X; Li LC; Mao S
Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
[TBL] [Abstract][Full Text] [Related]
4. Effect of Compression on the Molecular Arrangement of Itraconazole-Soluplus Solid Dispersions: Induction of Liquid Crystals or Exacerbation of Phase Separation?
Singh A; Bharati A; Frederiks P; Verkinderen O; Goderis B; Cardinaels R; Moldenaers P; Van Humbeeck J; Van den Mooter G
Mol Pharm; 2016 Jun; 13(6):1879-93. PubMed ID: 27092396
[TBL] [Abstract][Full Text] [Related]
5. Spherical crystal agglomeration technique for improved flow properties and oral bioavailability of atazanavir sulphate.
Shah D; Rawat J; Thakkar H
Ther Deliv; 2023 Apr; 14(4):269-280. PubMed ID: 37340886
[TBL] [Abstract][Full Text] [Related]
6. Design of spray dried ternary solid dispersions comprising itraconazole, soluplus and HPMCP: Effect of constituent compositions.
Davis MT; Potter CB; Mohammadpour M; Albadarin AB; Walker GM
Int J Pharm; 2017 Mar; 519(1-2):365-372. PubMed ID: 28131850
[TBL] [Abstract][Full Text] [Related]
7. Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid.
Piao ZZ; Choe JS; Oh KT; Rhee YS; Lee BJ
Eur J Pharm Sci; 2014 Jan; 51():67-74. PubMed ID: 24012590
[TBL] [Abstract][Full Text] [Related]
8. Spherical agglomeration to improve dissolution and micromeritic properties of an anticancer drug, Bicalutamide.
Dalvadi H; Parmar K; Yadav S
Drug Dev Ind Pharm; 2019 Jun; 45(6):968-980. PubMed ID: 30784326
[TBL] [Abstract][Full Text] [Related]
9. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
10. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
11. Formulation and evaluation of liquisolid compacts of itraconazole to enhance its oral bioavailability.
Thakkar HP; Vasava D; Patel AA; Dhande RD
Ther Deliv; 2020 Feb; 11(2):83-96. PubMed ID: 31955698
[No Abstract] [Full Text] [Related]
12. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC.
Wang X; Michoel A; Van den Mooter G
Int J Pharm; 2004 Mar; 272(1-2):181-7. PubMed ID: 15019081
[TBL] [Abstract][Full Text] [Related]
13. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability.
Kapsi SG; Ayres JW
Int J Pharm; 2001 Oct; 229(1-2):193-203. PubMed ID: 11604272
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
Desai C; Prabhakar B
Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
[TBL] [Abstract][Full Text] [Related]
16. The use of a new hydrophilic polymer, Kollicoat IR, in the formulation of solid dispersions of Itraconazole.
Janssens S; de Armas HN; Remon JP; Van den Mooter G
Eur J Pharm Sci; 2007 Mar; 30(3-4):288-94. PubMed ID: 17204410
[TBL] [Abstract][Full Text] [Related]
17. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
[TBL] [Abstract][Full Text] [Related]
18. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement.
Sathigari SK; Ober CA; Sanganwar GP; Gupta RB; Babu RJ
J Pharm Sci; 2011 Jul; 100(7):2952-65. PubMed ID: 21344415
[TBL] [Abstract][Full Text] [Related]
19. Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique.
Choi YK; Poudel BK; Marasini N; Yang KY; Kim JW; Kim JO; Choi HG; Yong CS
Int J Pharm; 2012 Sep; 434(1-2):264-71. PubMed ID: 22643224
[TBL] [Abstract][Full Text] [Related]
20. Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability.
Thakkar HP; Khunt A; Dhande RD; Patel AA
J Microencapsul; 2015; 32(6):559-69. PubMed ID: 26333939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
